Library | ImmunoSite Technologies

10/03/2017

ISO 9001:2015 and ISO 13485:2016

Desculpe-nos, mas este texto esta apenas disponível em English. Share this:

Share this:

05/22/2014

(English) Biomarkers Enhance Astra Zeneca's Clinical Trial Successes

Tags: Biomarker, Clinical Trials, Drug Development

(English) Biomarker data from Astra Zeneca demonstrates that biomarkers enhance success in every aspect (safety, dosing, efficacy, patient selection) of every state of the drug development process.

Share this:

02/10/2014

ImmunoSite Receives 2013 Innovative Business Award

(English) ImmunoSite Technologies, LLC receives the 2013 Innovative Business award

Share this:

02/02/2014

ImmunoSite Receives National MBE Certification

Desculpe-nos, mas este texto esta apenas disponível em English. Share this:

Share this:

06/29/2013

Feasibility study: Improving Cryopreservation of PBMC for More Reliable Information From Clinical Trials

Tags: Assay Automation, Clinical Trials, IST Partnerships

Advanced automation of PBMC freezing (cryopreservation) and cell thawing improved the quantity and quality of PBMC yields and viability. through a partnership between ImmunoSite Technologies and MéCour.

Share this:

06/14/2013

Blood, Sweat, and Robots

Tags: Assay Automation, Assay Standardization, Biomarker, Biotech, Drug Development, Vaccine Development

Bill Malone wrote a great article for Clinical laboratory News (American Assoc for Clinical Chemistry) that goes straight to the heart of the folklore and myth surrounding the use of automation in laboratories. Check out “Blood, Sweat, and Robots.” Share this:

Share this:

03/03/2013

ImmunoSite Technologies Expands into New Spacious Facility in Miramar

Tags: Assay Automation, ImmunoSite Technologies, Particle Testing, R&D Support, Services

Press Release, February 28, 2013 ImmunoSite Technologies, LLC (IST), a provider of automation, design and customization of complex biological assays to biotechnology and pharmaceutical industries worldwide, announced its relocation to a newly expanded facility at 2831 Corporate Way in Miramar. With the expansion, the company will be retaining its current employees, making a capital investment […]

Share this:

01/19/2013

2013 SLAS 2nd Annual Conference & Exhibition

Tags: Assay Automation, ImmunoSite Technologies, IST Partnerships, Services

Executives, Engineers, and Scientists from ImmunoSite Technologies attended the Annual 2013 SLAS meeting in Orlando, Florida and brought back some of the latest technologies to integrate into new automated solutions for biological assay automation that will enhance their client’s productivity even more! Call IST to discuss your automation needs at (888) 770-4478 Share this:

Share this:

10/18/2012

ImmunoSite Technologies Aides in Curriculum Development for Employ Florida Banner Center

Tags: BioFlorida, ImmunoSite Technologies, IST Partnerships

Cell Culture Course helps Floridians enter, remain and advance in the workforce Full release click here. Fort Lauderdale, Fla. – October 18, 2011 – ImmunoSite Technologies (IST), LLC, a leading provider of immune monitoring services, has helped to develop a Cell Culture Workshop that is offered at the Employ Florida Banner Center for Life Sciences, […]

Share this:

05/07/2012

Assay Automation Ability - Lyophilized reagents for in vitro whole blood assays

Tags: Assay Automation, Assay Standardization, Biomarker, Biotech, Cell Mediated Immune Assays, Drug Development, Immune Monitoring, Pharma

The need to implement robust biomarkers in clinical trials has never been greater, and such efforts can be easily compromised by reagent instability or simple human error during assay set-up. Many biotechnology and pharmaceutical companies are introducing efforts to conduct biomarker studies under more rigorous settings, and the use of plates or tubes pre-loaded with stimulation or staining reagents could be of value for studies that involve flow cytometry.
The value of this approach is that it lends itself to assay automation easily and safeguards against omission or erroneous addition of bulk liquid formulations of PMA and ionomycin to the reaction vessel (i.e., plate or tube) and also lends itself to extended stability/shelf-life of these reagents. On the basis of this initial success, we plan to expand our evaluation of lyophilized reagents so that they can be incorporated into our clinical biomarker campaigns as appropriate.

Share this:

Keep In Touch